Gastrointestinal damage by non-steroidal anti-inflammatory drugs: Updated clinical considerations

Minerva Gastroenterologica e Dietologica

Volumn 60, Issue 4, 2014, Pages 255-261

  Pellicano, R ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Anti inflammatory agents; Colitis; Enteritis; Helicobacter pylori; Non steroidal; Peptic ulcer

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL PLUS TRAMADOL; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ANTIPYRETIC AGENT; PARACETAMOL;

COMORBIDITY; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG INDUCED DISEASE; DUODENUM INJURY; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE; MEMBRANE PERMEABILITY; MORTALITY; PAIN INTENSITY; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RISK FACTOR; STOMACH PH; STOMACH PROTECTION; SYSTEMATIC REVIEW; AGE; CHEMICALLY INDUCED; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; ITALY; PEPTIC ULCER;

ACETAMINOPHEN; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRETICS; CYCLOOXYGENASE 2 INHIBITORS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; ITALY; PEPTIC ULCER; RISK FACTORS;

EID: 84923791841     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Cryer B. NSAIDS gastrointestinal toxicity. Curr Opin Gastroenterol 2000; 16: 495-502.
2. Singh G, Triafilopoulos G Epidemiology of FANS-induced gastrointestinal complications. J Reumathol 1999; 26: 18-24.
3. Kurata JH, Nogawa AN Meta-analysis of risk factors for peptic ulcer. J Clin Gastroenterol 1997; 24:2-17.
4. Henry D, Lim LL-Y, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M et al. Variability in risk of gastrointestianl complications with individual nonsteroidal anti-inflammatory drugs results of a collaborative meta-analysis. BMJ 1996; 312:1563-6.
5. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvanceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384-93
6. Sbrozzi-Vanni A, Zullo A, Di Giulio E, Hassan C, Corleto V.D., Lahner E et al. Low prevalence of idiopathic peptic ulcer disease: an Italian endoscopic survey. Dig Liver Dis 2010; 42: 773-6
7. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leucocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109: 1173-80
8. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355:646-8
9. Lanza FL, Chan FKL, Quigley EMM and the Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38
10. Robinson M, Mills RJ, Euler AR. Ranitidine prevents duodenal ulcers associated with non-steroidal antiinflammatory drug therapy. Aliment Pharmacol Ther 1991; 5:143-50.
11. Coxib and traditional NSAID Trialists (CNT) Collaboration Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs meta-analyses of individual participant data from randomised trials. Lancet 2013; 382:769-79.
12. Cannon CP, Curtis SP, Fitzgerald G.A., Krum H., Kaur A, Bolognese JA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoncoxib and Diclofenac Arthritis Long-term (MEDAL) programme a randomised comparison. Lancet 2006; 368:1771-81.
13. Silverstein FE, Faich G, Goldstein J.L., Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-55
14. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ 2002; 324:1287-8.
15. Crofford LJ, Lipsky PE, Brooks P, Abramson S.B., Simon LS, van de Putte LB Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43: 4-13
16. Jackson LM, Wu KC, Mahida Y.R., Jenkins D., Hawkey CJ Cycloxygenase (COX)1 and 2 in normal, inflamed and ulcerated human gastric mucosa. Gut 2000; 47: 762-70
17. Wallace JL, Bak A, McKmght W., Ashafa S, Sharkey KA, MacNaughton WK Cyclooxygenase 1 contributes to inflammatory response in rats and mice implications for gastrointestinal toxicity. Gastroenterology 1998; 115: 101-9.
18. Mizuno H, Sakamoto C, Matsuda K., Wada K, Uchida T, Noguchi H et al. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by specific antagonists delays healing in mice. Gastroenterology 1997; 112: 387-97.
19. Cannon GW, Caldwell JR, Holt P, McLean B., Seidenberg B, Bolognese J et al. Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that of diclofenac sodium results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 978-86
20. Mallen SR, Essex MN, Zhang R. Gastrointestinal toler-ability of NSAIDs in elderly patients a pooled analysis of 21 randomized clinical trials with celecoxib and non-selective NSAIDs. Curr Med Res Opin 2011; 27: 1359-66
21. Rodriguez Garcia LA, Cattaruzzi C, Troncon M.G., Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other non-steroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33-9.
22. Rodriguez LAG Variability in risk of gastrointestinal complications with different NSAIDs. Am T Med 1998; 104: 30S-34S
23. Insel PA Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In Goodman and Gilman, editors. The pharmacological basis of therapeutics. 9th ed New York McGraw-Hill; 1996 p. 617-57.
24. Pellicano R, Guerra L Skin ulcer pain. Minerva Med 2012; 103: 525-31
25. Lim YJ, Chun HJ. Recent advances in NSAIDs-induced enteropathy therapeutics new options, new challenges. Gastroenterol Res Pract 2013; 2013: 761060
26. Cannizzaro O, Cammarota G, Gasbarrini A., Cianci R, Cuoco L, Montalto M et al. FANS e tratto intestinale In Cammarota G, Gasbarrini G, editors Le patologie esofago-gastro-intestinah da FANS Milano: Mediserve, 2000; p 101-10
27. Chan FKL, Lanas A, Scheiman J., Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR). a randomised trial. Lancet 2010; 376: 173-9
28. Wallace JL, Syer S, Denou E., De Palma G, Vong L, McKnight W et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-22